Skip to main content
Article thumbnail
Location of Repository

Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection

By Stephen A. Beers, Ruth R. French, Claude H.T. Chan, Sean H. Lim, Timothy C. Jarrett, Regina Mora Vidal, Sahan S. Wijayaweera, Sandra V. Dixon, Hyung J. Kim, Kerry L. Cox, Jonathan P. Kerr, David A. Johnston, Peter W.M. Johnson, Sjef Verbeek, Martin J. Glennie and Mark S. Cragg


Rituximab, a monoclonal antibody which targets CD20 on B-cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success a substantial proportion of B-cell lymphomas are unresponsive or develop resistance, hence more potent anti-CD20 mAb are continually being sought. Here we demonstrate that type II (tositumomab-like) anti-CD20 mAb are 5 times more potent than type I (rituximab-like) reagents in depleting human CD20 Tg B-cells, despite both operating exclusively via activatory FcR-expressing macrophages. Much of this disparity in performance is attributable to type I mAb-mediated internalization of CD20 by B-cells leading to reduced macrophage recruitment and the degradation of CD20:mAb complexes, shortening mAb half-life. Importantly, human B cells from healthy donors, and most cases of Chronic Lymphatic Leukemia (CLL) and Mantle Cell Lymphoma, showed rapid CD20 internalization which paralleled that seen in the Tg mouse B cells, while most Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) cells were far more resistant to CD20 loss. We postulate that differences in CD20 modulation may play a central role in determining the relative efficacy of rituximab in treating these diseases and strengthen the case for focusing on type II anti-CD20 mAb in the clinic. <br/><br/

Topics: RC0254
Year: 2010
OAI identifier:
Provided by: e-Prints Soton

Suggested articles


  1. Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. doi
  2. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. doi
  3. Apparent modulation of CD20 by rituximab: an alternative explanation. Blood. 2004;103(10):3989-3990; author reply 3990-3981.
  4. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis.
  5. CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. Cancer research.
  6. Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. doi
  7. Chemotherapy exposure increases leukemia cell stiffness. doi
  8. Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. doi
  9. Depletion of B cells in murine lupus: efficacy and resistance. doi
  10. Emerging information on the use of rituximab in chronic lymphocytic leukemia. Semin Oncol. doi
  11. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer research.
  12. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. doi
  13. (1999). Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol.
  14. Fc gamma RIIIa and Fc gamma RIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia. doi
  15. Fc receptors and cancer. Current opinion in immunology. doi
  16. Higher levels of surface CD20 expression on circulating lymphocytes compared with bone marrow and lymph nodes in B-cell chronic lymphocytic leukemia. doi
  17. Homotypic adhesion and lysosomemediated cell death evoked by
  18. (2005). HuMax CD20 Fully Human Monoclonal Antibody in Chronic Lymphocytic Leuchemia. Early Results from an Ongoing Phase I/II Clinical Trial. ASH Annual Meeting Abstracts.
  19. Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy. doi
  20. (2010). Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct- and immune effector cell-mediated B-cell cytotoxicity. doi
  21. Induction of cytosolic calcium flux by CD20 is dependent upon B Cell antigen receptor signaling. doi
  22. (2000). Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nature medicine.
  23. Intracellular accumulation of the anti-CD20 antibody 1F5 in B-lymphoma cells. Clin Cancer Res.
  24. (1996). Kupffer cell depletion by liposome-delivered drugs: comparative activity of intracellular clodronate, propamidine, and ethylenediaminetetraacetic acid. Hepatology doi
  25. Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage FcgammaRI, FcgammaRIII, and FcgammaRIV. doi
  26. Mechanisms of killing by antiCD20 monoclonal antibodies. Mol Immunol.
  27. Monoclonal antibody 1F5 (antiCD20) serotherapy of human B cell lymphomas.
  28. (1998). Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors.
  29. Phase 1/2 study of fractionated (131)Irituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. doi
  30. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.
  31. Radiation therapy with tositumomab (B1) anti-CD20 monoclonal antibody initiates extracellular signal-regulated kinase/mitogen-activated protein kinase-dependent cell death that overcomes resistance to apoptosis. Clin Cancer Res. doi
  32. (1994). Retention of B-cell-specific monoclonal antibodies by human lymphoma cells.
  33. Rituxan (anti-CD20 antibody)-induced translocation of CD20 into lipid rafts is crucial for calcium influx and apoptosis. Clinical and experimental immunology. doi
  34. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.
  35. Rituximab dose-escalation trial in chronic lymphocytic leukemia.
  36. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. doi
  37. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. doi
  38. (2006). Significant Correlation between Survival Endpoints and Exposure to Ofatumumab (HuMax-CD20) in Chronic Lymphocytic Leukemia. ASH Annual Meeting Abstracts.
  39. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. doi
  40. The antileukemia activity of a human antiCD40 antagonist antibody, HCD122, on human chronic lymphocytic leukemia cells. doi
  41. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. doi
  42. The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy. doi
  43. The peritoneal cavity provides a protective niche for B1 and conventional B lymphocytes during anti-CD20 immunotherapy in mice. doi
  44. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. doi
  45. Therapeutic activity of humanized antiCD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. doi
  46. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. doi
  47. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. doi
  48. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. doi
  49. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation. doi
  50. VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. doi
  51. von dem Borne AE, SlaperCortenbach IC. Preclinical studies with radiolabeled monoclonal antibodies for treatment of patients with B-cell malignancies. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.